Liu Dan, Wang Fang, Sun Ling, Liu Lin-Xiang, Liu Yan-Fang, Ling Zhi, Han Xue-Fei
Department of Hematology, Zhengzhou University First Hospital, and Research Center of Stem Cells, Zhengzhou University Basic Medical College, Zhengzhou 450052, Henan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1168-71.
This study was purposed to investigate the effect of gemcitabine (GEM) on granulocyte colony-stimulating factor receptor (G-CSFR) and bcr/abl mRNA in patients with chronic myeloid leukemia (CML). 23 cases of CML in chronic phase, 8 cases of CML in blastic phase and 10 cases of non-hematologic diseases with normal bone marrow were enrolled in this study. The bone marrow from all these cases was collected and divided into 2 group: GEM group (bone marrow cells of CML patients and normal bone marrow cells were cultured with 10 µg/ml GEM for 48 hours) and control group (above-mentioned bone marrow cells were cultured without GEM for 48 hours). The expression of G-CSFR was detected by flow cytometry, the expression of bcr/abl mRNA was assayed by RT-PCR. The results showed that the G-CSFR expression rates of bone marrow in CML chronic phase and blastic phase as well as normal bone marrow in GEM group were (50.72±8.57)%, (36.32±4.25)% and (59.42±7.62)% respectively, while the G-CSFR expression rates of above-mentioned bone marrow in control group were (45.42±6.52)%, (30.58±5.68)% and (58.56±5.54)% respectively. The comparison of G-CSFR expression rates between bone marrow of CML and normal bone marrow, between bone marrow of chronic phase and blastic phase and between bone marrow of GEM group and control group all demonstrated significant difference (p<0.05). The RT-PCR assay showed that the expressions of bcr/abl mRNA in CML chronic and blastic phases of GEM group were (0.59±0.15)% and (0.60±0.13)% respectively, while above-mentioned indicators of control group were (0.60±0.10)% and (0.63±0.11)%; there was no significant difference on expression of bcr/abl mRNA between GEM and control groups (p>0.05). The negative correlation of G-CSFR expression rate with bcr/abl mRNA expression level was observed in GEM and control groups as well as in CML chronic phase and blastic phase of GEM group (r=-0.747, p<0.01; r=-0.803, p<0.01 respectively). It is concluded that the GEM can in vitro enhance the expression rate of bone marrow G-CSFR in CML patients at chronic or blastic phases, but no significant effect on expression of bcr/abl mRNA. The negative correlation of G-CSFR expression rate with bcr/abl mRNA expression level exists in CML patients at chronic or blastic phases.
本研究旨在探讨吉西他滨（GEM）对慢性髓性白血病（CML）患者粒细胞集落刺激因子受体（G-CSFR）及bcr/abl mRNA的影响。本研究纳入23例慢性期CML患者、8例急变期CML患者及10例骨髓正常的非血液系统疾病患者。收集所有这些患者的骨髓并分为2组：GEM组（CML患者的骨髓细胞及正常骨髓细胞用10μg/ml GEM培养48小时）和对照组（上述骨髓细胞不用GEM培养48小时）。采用流式细胞术检测G-CSFR的表达，采用逆转录聚合酶链反应（RT-PCR）检测bcr/abl mRNA的表达。结果显示，GEM组CML慢性期和急变期骨髓以及正常骨髓的G-CSFR表达率分别为（50.72±8.57）%、（36.32±4.25）%和（59.42±7.62）%，而对照组上述骨髓的G-CSFR表达率分别为（45.42±6.52）%、（30.58±5.68）%和（58.56±5.54）%。CML骨髓与正常骨髓之间、慢性期与急变期骨髓之间以及GEM组与对照组骨髓之间G-CSFR表达率的比较均显示出显著差异（p<0.05）。RT-PCR检测显示GEM组CML慢性期和急变期bcr/abl mRNA的表达分别为（0.59±0.15）%和（0.60±0.13）%，而对照组上述指标分别为（0.60±0.10）%和（0.63±0.11）%；GEM组与对照组bcr/abl mRNA的表达无显著差异（p>0.05）。在GEM组和对照组以及GEM组CML慢性期和急变期均观察到G-CSFR表达率与bcr/abl mRNA表达水平呈负相关（r分别为-0.747，p<0.01；-0.803，p<0.01）。结论是，GEM可在体外提高慢性或急变期CML患者骨髓G-CSFR的表达率，但对bcr/abl mRNA的表达无显著影响。慢性或急变期CML患者存在G-CSFR表达率与bcr/abl mRNA表达水平的负相关。
